Takafumi Fuchiwaki

Shimane University, Matsu, Shimane, Japan

Are you Takafumi Fuchiwaki?

Claim your profile

Publications (5)7.8 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To determine the mechanisms by which a traditional herbal medicine, Senkinnaidakusan (SKNS), controls Th2 responses, we examined the production of IL-12 by murine macrophages treated with SKNS. Results: Treatment with SKNS significantly increased TLR4 mRNA in macrophages. Furthermore, pre-treatment with SKNS enhanced the production of IL-12 by macrophages stimulated with LPS. When SKNS was orally administered to C3H/HeN mice at the induction phase after OVA sensitization, the serum levels of OVA-specific immunoglobulin (Ig)E and IgG1 decreased, Interleukin (IL)-4 production by spleen T cells in response to OVA was significantly suppressed, while interferon (IFN)-gamma production was increased. After nasal challenge of OVA, eosinophilic infiltration in the nasal mucosa and the number of sneezes were significantly inhibited in SKNS-treated mice compared with control mice. Besides, expression of IL-5 in the nasal mucosa was also inhibited. Using another strain of mice, C3H/HeJ (TLR4 negative), there was no difference in OVA-specific Igs or splenic cytokine production between the SKNS treatment and non-treatment groups. The eosinophilic infiltration in the nasal mucosa, the number of sneezes and IL-5 expression in the nasal mucosa were also not effected even after SKNS treatment. Conclusion: These results suggest that oral administration of SKNS inhibits Th2 responses by enhancement of IL-12 release from macrophages via up-regulation of TLR4 expression.
    Rhinology 09/2014; 52(3):252-259. DOI:10.4193/Rhino11.269 · 3.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Deep neck abscesses represent an emergency otolaryngological disease. We analyzed 25 patients with deep neck abscesses treated in our hospital between 1998 and 2009. The mean age of the patients was 58.9 years. We investigated the age, primary focus, extension of the abscess, treatment, causative bacteria and prognosis. The cause of the deep neck abscesses was pharyngeal infection in 9 cases (36%), odontogenic infection in 5 cases (20%), peritonsillar abscess in 3 cases (12%), and a foreign body (fish bones) in 3 cases (12%). Each case of deep neck abscess was classified according to the degree of extent of infection diagnosed with CT imaging. The abscesses were localized in the upper neck space above the hyoid bone in 10 cases, extended to the lower hyoid bone in 8 cases, and extended to the mediastinum in 7 cases. As regards causative bacteria, there was a mixture of aerobic and anaerobic bacteria-related infection in 11 cases (44%). Severe single aerobic infection was seen in 9 cases (36%), and Streptococcus pyogenes (S. pyogenes) was seen in 4 cases (16%). Progression to the mediastinal space occurred in 4 cases of the mixed infection type and in 3 cases of S. pyogenes infection. As for the sensitivity of the causative bacteria to antibacterial drugs, the anaerobic bacteria demonstrated 89% resistance to penicillin. It was thought that anaerobic bacteria produced b lactamase. Our treatment principle for deep neck abscesses is hospitalization, followed by incision and drainage of the abscess and intravenous administration of a wide spectrum antibacterial agent. Though there serious cases have been reported such as descending necrotizing mediastinitis and/or necrotizing fasciitis, all 25 cases we treated were successfully cured without any severe complication.
    Practica Otologica 01/2014; 107(7):569-577. DOI:10.5631/jibirin.107.569
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sublingual immunotherapy (SLIT) has been considered to be a painless and efficacious therapeutic treatment of allergic rhinitis which is known as type I allergy of nasal mucosa. Nevertheless, its mechanisms need to be further investigated. In this study, we constructed an effective murine model of sublingual immunotherapy in allergic rhinitis, in which mice were sublingually administered with ovalbumin (OVA) followed by intraperitoneal sensitization and nasal challenge of OVA. Sublingually treated mice showed significantly decreased specific IgE responses as well as suppressed Th2 immune responses. Sublingual administration of OVA did not alter the frequency of CD4+CD25+ regulatory T cells (Tregs), but led to upregulation of Foxp3- and IL-10-specific mRNAs in the Tregs of cervical lymph nodes (CLN), which strongly suppressed Th2 cytokine production from CD4+CD25− effector T cells in vitro. Furthermore, sublingual administration of plasmids encoding the lymphoid chemokines CCL19 and CCL21-Ser DNA together with OVA suppressed allergic responses. These results suggest that IL-10-expressing CD4+CD25+Foxp3+ Tregs in CLN are involved in the suppression of allergic responses and that CCL19/CCL21 may contribute to it in mice that received SLIT.
    Journal of Allergy 10/2012; 2012:490905. DOI:10.1155/2012/490905
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CD30 ligand (CD30L) plays an important role in the amplification and/or activation of effector CD4(+) T cells, irrespective of Th cell subset. To examine the role of CD30L in allergic rhinitis, we evaluated an OVA model of allergic rhinitis in CD30L knock out (KO) mice on a BALB/c background sensitized with OVA. Symptoms of allergic rhinitis such as eosinophil infiltration into the nasal mucosa were drastically diminished in OVA-sensitized CD30L KO mice following intranasal challenge with OVA. The levels of OVA-specific IgE in the sera and the Th2 response in nasopharynx-associated lymphoid tissues and cervical LNs of CD30L KO mice were significantly lower than those of WT mice following intranasal challenge with OVA. Intranasal administration of CD30-Ig during the effector phase with OVA significantly prevented the development of allergic rhinitis in WT mice. These results suggest that CD30L plays an important role in allergic rhinitis and that the inhibition of CD30L/CD30 signaling might be useful as a novel biological therapy for allergic rhinitis.
    European Journal of Immunology 10/2011; 41(10):2947-54. DOI:10.1002/eji.201141423 · 4.03 Impact Factor
  • Kaoru Goda · Takaya Yamada · Miki Tongu · Takafumi Fuchiwaki · Chiaki Sano · Hideyuki Kawauchi ·

    01/2010; 49(1):90-90. DOI:10.7248/jjrhi.49.90

Publication Stats

10 Citations
7.80 Total Impact Points


  • 2012-2014
    • Shimane University
      • Faculty of Medicine
      Matsu, Shimane, Japan
  • 2011
    • Kyushu University
      • Division of Host Defense
      Hukuoka, Fukuoka, Japan